Evidence map›Paper›PMID 38201220›Full record

ArticleCells2023

Absent in Melanoma (AIM)2 Promotes the Outcome of Islet Transplantation by Repressing Ischemia-Induced Interferon (IFN) Signaling.

Selina Wrublewsky, Cedric Wilden, Caroline Bickelmann, Michael D Menger, Matthias W Laschke, Emmanuel Ampofo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Selina WrublewskyInstitute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg, Germany.
Cedric WildenInstitute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg, Germany.
Caroline BickelmannInstitute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg, Germany.
Michael D MengerInstitute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg, Germany.
Matthias W LaschkeInstitute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg, Germany.ORCID 0000-0002-7847-8456
Emmanuel AmpofoInstitute for Clinical & Experimental Surgery, Saarland University, 66421 Homburg, Germany.ORCID 0000-0002-1886-5657
Saarland University · DE

Funding

Deutsche Forschungsgemeinschaft AM 640/2-1
6 · The paper itself

Abstract

Clinical islet transplantation is limited by ischemia-induced islet cell death. Recently, it has been reported that the absent in melanoma (AIM)2 inflammasome is upregulated by ischemic cell death due to recognition of aberrant cytoplasmic self-dsDNA. However, it is unknown whether AIM2 determines the outcome of islet transplantation. To investigate this, isolated wild type (WT) and

Indexed as

Diabetes Mellitus, ExperimentalIslets of Langerhans TransplantationMelanomaAnimalsCytokinesDisease Models, AnimalInterferonsMiceCytokinesInterferonsAIM2inflammasomeinterferonislet transplantationrevascularization

Identifiers

PMID38201220
PMCPMC10778091
OpenAlexW4390007676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.